• Piri Keşif Aracı

Arama ipuçları nelerdir?
1.  sayfa ve
1
Airborne precautions are needed against COVID-19
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
Journal of Infection and Public Health
Yazar(lar) :
Yoshiyasu Takefuji
Yıl :
2020
Airborne precautions are needed against COVID-19
Yayıncı Web Sitesi
Kaydet Alıntıla
Cilt: 13
Sayı: 6
Sayfa: 833
Sınıflandırma :
2
Molecular Aspects of COVID-19 Differential Pathogenesis
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak 1:
Directory of Open Access Journals (DOAJ)
Kaynak 2:
MDPI
Dergi:
Pathogens
Yazar(lar) :
Hussin A. Rothan , Arpan Acharya , St Patrick Reid , Mukesh Kumar , Siddappa N. Byrareddy
Yıl :
2020
Molecular Aspects of COVID-19 Differential Pathogenesis In the absence of therapeutic interventions, and a possible vaccine candidate, the spread of COVID- 19 disease and associated fatalities are on the rise The epidemiological data indicate that age, sex, and cardio-metabolic disease have a significant impact on the spread and severity of COVID- 19. COVID-19
Piri Tam Metin Bulucu
Kaydet Alıntıla
In the absence of therapeutic interventions, and a possible vaccine candidate, the spread of COVID-19 disease and associated fatalities are on the rise. The high mutation frequency in the genomic material of these viruses supports their ability to adapt to new environments, resulting in an efficient alteration in tissue tropism and host range. Therefore, the coronavirus’ health threats could be relevant for the long-term. The epidemiological data indicate that age, sex, and cardio-metabolic disease have a significant impact on the spread and severity of COVID-19. In this review, we highlight recent updates on the pathogenesis of SARS-CoV-2 among men and women, including children. We also discuss the role of the cellular receptors and coreceptors used by the virus to enter host cells on differential infection among men, women, and cardio-metabolic patients.
DOI : 10.3390/pathogens9070538
Anahtar Kelimeler : SARS-COV-2, COVID-19, differential pathogenesis, comorbidity, cardio-metabolic disease
ISSN: 2076-0817
Cilt: 9
Sayı: 538
Sayfa: 538
Sınıflandırma :
3
COVID-19 Therapeutic and Prevention
Dergi Makalesi

Dergi Makalesi
Kaynak :
Science Direct
Dergi:
International Journal of Antimicrobial Agents
Yayıncı:
Elsevier
Yazar(lar) :
Didier Raoult , Po-Ren Hsueh , Stefania Stefani , Jean-Marc Rolain
Yıl :
2020
COVID-19 Therapeutic and Prevention
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
DOI : 10.1016/j.ijantimicag.2020.105937
ISSN: 0924-8579
Sayı: 4
Cilt: 55
Sayfa: 105937
Sınıflandırma :
4
COVID-19 and the Eye
Dergi Makalesi

Dergi Makalesi
Kaynak :
Science Direct
Dergi:
Journal of Infection
Yayıncı:
Elsevier
Yazar(lar) :
Yueyang Zhong , Kai Wang , Yanan Zhu , Danni Lyu , Ke Yao
Yıl :
2020
COVID-19 and the Eye
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
DOI : 10.1016/j.jinf.2020.05.054
ISSN: 0163-4453
Sayı: 2
Cilt: 81
Sayfa: e122-e123
Sınıflandırma :
5
Of chloroquine and COVID-19
Dergi Makalesi

Dergi Makalesi
Kaynak :
Science Direct
Dergi:
Antiviral Research
Yayıncı:
Elsevier
Yazar(lar) :
Franck Touret , Xavier de Lamballerie
Yıl :
2020
Of chloroquine and COVID-19 COVID-19
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
Recent publications have brought attention to the possible benefit of chloroquine, a broadly used antimalarial drug, in the treatment of patients infected by the novel emerged coronavirus (SARS-CoV-2). The scientific community should consider this information in light of previous experiments with chloroquine in the field of antiviral research.
DOI : 10.1016/j.antiviral.2020.104762
Anahtar Kelimeler : SARS-CoV-2, COVID-19, 2019-nCoV, Chloroquine, Antiviral
ISSN: 0166-3542
Cilt: 177
Sayfa: 104762
Sınıflandırma :
6
COVID-19 precautions and recommendations
Dergi Makalesi

Dergi Makalesi
Kaynak :
Science Direct
Dergi:
American Journal of Orthodontics and Dentofacial Orthopedics
Yayıncı:
Elsevier
Yazar(lar) :
Prabhat Kumar Chaudhari , Jitendra Sharan , Kelly Kathering Achachao Almerco
Yıl :
2020
COVID-19 precautions and recommendations
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
DOI : 10.1016/j.ajodo.2020.06.015
ISSN: 0889-5406
Sayı: 3
Cilt: 158
Sayfa: 312
Sınıflandırma :
7
Azithromycin for severe COVID-19
Dergi Makalesi

Dergi Makalesi
Kaynak :
Science Direct
Dergi:
The Lancet
Yayıncı:
Elsevier
Yazar(lar) :
Catherine E Oldenburg , Thuy Doan
Yıl :
2020
Azithromycin for severe COVID-19
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
DOI : 10.1016/s0140-6736(20)31863-8
ISSN: 0140-6736
Sayı: 10256
Cilt: 396
Sayfa: 936-937
Sınıflandırma :
8
Pathology and Therapeutics of COVID-19: A Review
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
International Journal of Medical Students
Yazar(lar) :
Haleema Anwar , Qudsia Umaira Khan
Yıl :
2020
Pathology and Therapeutics of COVID-19: A Review COVID- 19 pandemic has taken over the world. COVID- 19 cases were first reported in December 2019 in China; it affects the lungs causing mild to severe respiratory disease. The article will provide a good insight into the COVID- 19 infection.
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet Alıntıla
COVID-19 pandemic has taken over the world. Spreading form its epicenter in a seafood market in Wuhan to more than 200 countries, it has caused alarming situations. The viral infection is caused by an RNA virus called SARS-CoV-2. Its genome resembles the SARS-CoV-1 and MERS-CoV genome. COVID-19 cases were first reported in December 2019 in China; it affects the lungs causing mild to severe respiratory disease. No antiviral drug for the infection has been approved yet, but certain drugs are under consideration including Chloroquine, Hydroxychloroquine and Teicoplanin. The review article will first present the structure of the SARS-CoV-2 and compare it to SARS-CoV-1 and MERS-CoV. The article will then highlight its effect on different organs. Finally, it will highlight the therapeutics which are in consideration and which are being used. The article will provide a good insight into the COVID-19 infection.
DOI : 10.5195/ijms.2020.498
Anahtar Kelimeler : pandemic, phylogenetic analysis, differential diagnosis, incubation period, viral genome
ISSN: 2076-6327
Sınıflandırma :
9
Procalcitonin levels in COVID-19 patients
Dergi Makalesi

Dergi Makalesi
Kaynak :
Science Direct
Dergi:
International Journal of Antimicrobial Agents
Yayıncı:
Elsevier
Yazar(lar) :
Rui Hu , Chaofei Han , Shiyao Pei , Mingzhu Yin , Xiang Chen
Yıl :
2020
Procalcitonin levels in COVID-19 patients Coronavirus disease 2019 ( COVID- 19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been declared a pandemic This study analysed 95 SARS-CoV-2-infected patients, including 62 moderate COVID- 19 patients, 21 severe COVID- 19 patients and 12 critical COVID- 19 patients We demonstrate that PCT may be an indicator of disease severity in COVID- 19 and may contribute to determining the severity of patients infected with SARS-CoV COVID-19
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
Coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been declared a pandemic. This study analysed 95 SARS-CoV-2-infected patients, including 62 moderate COVID-19 patients, 21 severe COVID-19 patients and 12 critical COVID-19 patients (6 patients died, all critical). The results showed that the mean serum procalcitonin (PCT) levels were over four times higher in severe patients than in moderate patients and were over eight times higher in critical patients than in moderate patients. For discharged patients, both high-normal PCT levels and abnormal PCT levels decreased during recovery. However, in death cases, serum levels of PCT increased as the disease worsened. We demonstrate that PCT may be an indicator of disease severity in COVID-19 and may contribute to determining the severity of patients infected with SARS-CoV-2. Moreover, serial PCT measurements may be useful in predicting the prognosis.
DOI : 10.1016/j.ijantimicag.2020.106051
Anahtar Kelimeler : Coronavirus, SARS-CoV-2, COVID-19, Procalcitonin, Severity, Prognosis
ISSN: 0924-8579
Sayı: 2
Cilt: 56
Sayfa: 106051
Sınıflandırma :
10
Extra-respiratory manifestations of COVID-19
Dergi Makalesi

Dergi Makalesi
Kaynak :
Science Direct
Dergi:
International Journal of Antimicrobial Agents
Yayıncı:
Elsevier
Yazar(lar) :
Chih-Cheng Lai , Wen-Chien Ko , Ping-Ing Lee , Shio-Shin Jean , Po-Ren Hsueh
Yıl :
2020
Extra-respiratory manifestations of COVID-19 Coronavirus disease 2019 ( COVID- 19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global health threat. clinical presentations associated with SARS-CoV-2 infection, allowing the consideration of COVID- 19 in differential diagnoses. - 19. COVID-19
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global health threat. Although most patients with COVID-19 manifest fever and respiratory tract symptoms, SARS-CoV-2 infection may also involve other organs/systems and present with extra-respiratory manifestations, including cardiac, gastrointestinal, hepatic, renal, neurological, olfactory, gustatory, ocular, cutaneous and haematological symptoms. Occasionally, these extra-respiratory symptoms/signs represent the initial presentation of SARS-CoV-2 infection, prior to fever or respiratory manifestations. Therefore, this comprehensive review of the extra-respiratory manifestations of COVID-19 is intended to help clinicians better understand the range of clinical presentations associated with SARS-CoV-2 infection, allowing the consideration of COVID-19 in differential diagnoses. A screening test for SARS-CoV-2 should be performed when patients have these extra-respiratory manifestations. In addition, clinicians should be alerted to the adverse effects of anti-SARS-CoV-2 agents that can mimic the extra-respiratory manifestations of COVID-19. Moreover, some extra-respiratory manifestations, such as ocular and gastrointestinal involvement, may be caused by direct invasion of SARS-CoV-2. Therefore, protective measures should be taken while managing the associated clinical specimens. Finally, several extra-respiratory manifestations, such as cardiac involvement, acute kidney injury, coagulation disorders and thrombotic complications, could be associated with a poor prognosis.
DOI : 10.1016/j.ijantimicag.2020.106024
Anahtar Kelimeler : COVID-19, SARS-CoV-2, Epidemiology, Extra-respiratory manifestations
ISSN: 0924-8579
Sayı: 2
Cilt: 56
Sayfa: 106024
Sınıflandırma :
11
Standing out from the crowd in treating COVID-19
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
Medicine in Drug Discovery
Yazar(lar) :
Kim D. Janda , Michael J. Iadarola
Yıl :
2020
Standing out from the crowd in treating COVID-19
Yayıncı Web Sitesi
Kaydet Alıntıla
ISSN: 2590-0986
Cilt: 6
Sayfa: 100034
Sınıflandırma :
12
Use of antiviral drugs to reduce COVID-19 transmission
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
The Lancet Global Health
Yazar(lar) :
Oriol Mitjà , Bonaventura Clotet
Yıl :
2020
Use of antiviral drugs to reduce COVID-19 transmission
Yayıncı Web Sitesi
Kaydet Alıntıla
ISSN: 2214-109X
Cilt: 8
Sayı: 5
Sayfa: e639 - e640
Sınıflandırma :
13
Drug repurposing against COVID-19: focus on anticancer agents
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
Journal of Experimental & Clinical Cancer Research
Yazar(lar) :
Gennaro Ciliberto , Rita Mancini , Marco G. Paggi
Yıl :
2020
Drug repurposing against COVID-19: focus on anticancer agents Abstract Background The very limited time allowed to face the COVID- 19 pandemic poses a pressing challenge to find proper therapeutic approaches. Most drugs considered for repurposing/repositioning in the therapy of the COVID- 19 outbreak are commercially available and their dosage and toxicity in Several drugs being re-considered for COVID- 19 therapy are or have been used in cancer therapy.
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet Alıntıla
Abstract Background The very limited time allowed to face the COVID-19 pandemic poses a pressing challenge to find proper therapeutic approaches. However, synthesis and full investigation from preclinical studies to phase III trials of new medications is a time-consuming procedure, and not viable in a global emergency, such as the one we are facing. Main Body Drug repurposing/repositioning, a strategy effectively employed in cancer treatment, can represent a valid alternative. Most drugs considered for repurposing/repositioning in the therapy of the COVID-19 outbreak are commercially available and their dosage and toxicity in humans is well known, due to years (or even decades) of clinical use. This can allow their fast-track evaluation in phase II–III clinical trials, or even within straightforward compassionate use. Several drugs being re-considered for COVID-19 therapy are or have been used in cancer therapy. Indeed, virus-infected cells are pushed to enhance the synthesis of nucleic acids, protein and lipid synthesis and boost their energy metabolism, in order to comply to the “viral program”. Indeed, the same features are seen in cancer cells, making it likely that drugs interfering with specific cancer cell pathways may be effective as well in defeating viral replication. Short Conclusion To our knowledge, cancer drugs potentially suitable for facing SARS-CoV-2 infection have not been carefully reviewed. We present here a comprehensive analysis of available information on potential candidate cancer drugs that can be repurposed for the treatment of COIVD-19.
DOI : 10.1186/s13046-020-01590-2
Anahtar Kelimeler : Health emergencies, Viral pneumonia, Anticancer drugs, Drug repurposing, Immune response
ISSN: 1756-9966
Cilt: 39
Sayı: 1
Sayfa: 1 - 9
Sınıflandırma :
14
Emerging vaccine delivery systems for COVID-19
Dergi Makalesi

Dergi Makalesi
Kaynak :
Science Direct
Dergi:
Drug Discovery Today
Yayıncı:
Elsevier
Yazar(lar) :
Nigel Theobald
Yıl :
2020
Emerging vaccine delivery systems for COVID-19
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
DOI : 10.1016/j.drudis.2020.06.020
ISSN: 1359-6446
Sayı: 9
Cilt: 25
Sayfa: 1556-1558
Sınıflandırma :
15
Current Status of COVID-19 Therapies and Drug Repositioning Applications
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
iScience
Yazar(lar) :
Ozlem Altay , Elyas Mohammadi , Simon Lam , Hasan Turkez , Jan Boren , Jens Nielsen , Mathias Uhlen , Adil Mardinoglu
Yıl :
2020
Current Status of COVID-19 Therapies and Drug Repositioning Applications rapid and global spread of a new human coronavirus (SARS-CoV-2) has produced an immediate urgency to discover promising targets for the treatment of COVID - 19. Here, we review current information concerning the global health issue of COVID- 19 including promising approved drugs and ongoing clinical trials for prospective
Yayıncı Web Sitesi
Kaydet Alıntıla
The rapid and global spread of a new human coronavirus (SARS-CoV-2) has produced an immediate urgency to discover promising targets for the treatment of COVID-19. Drug repositioning is an attractive approach that can facilitate the drug discovery process by repurposing existing pharmaceuticals to treat illnesses other than their primary indications. Here, we review current information concerning the global health issue of COVID-19 including promising approved drugs and ongoing clinical trials for prospective treatment options. In addition, we describe computational approaches to be used in drug repurposing and highlight examples of in silico studies of drug development efforts against SARS-CoV-2.
Anahtar Kelimeler : Health Sciences, Medicine
ISSN: 2589-0042
Cilt: 23
Sayı: 7
Sayfa: 101303
Sınıflandırma :
16
Amphotericin B as antiviral drug: Possible efficacy against COVID-19
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
Annals of Thoracic Medicine
Yazar(lar) :
Falah Hasan Obayes AL-Khikani
Yıl :
2020
Amphotericin B as antiviral drug: Possible efficacy against COVID-19 COVID- 19 is regarding the new genera of coronaviridae that appear the first time in Wuhan, China, in early December 2019. Due to the continuous spreading of the novel COVID- 19 with the exponential rise in death numbers, new therapeutic development is urgent, in general, there - 19. covid-19
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet Alıntıla
Since its discovery, amphotericin B (AmB) is still one of the most common first-line choices in treatment pulmonary mycoses for over seventh decades from discovery. AmB which is belonged to the polyene group has a wide spectrum in vitro and in vivo antimicrobial activity against fungi and parasites, resistance to AmB is rare despite extensive use. Recently, some studies focused on the potential antimicrobial action of AmB against some enveloped viruses such as human immunodeficiency virus, Japanese encephalitis virus, and rubella virus. Coronaviruses are enveloped positive-sense RNA nucleic acid viruses that have club-like spikes, characterized by a distinctive replication strategy; they are round and sometimes pleomorphic shapes. COVID-19 is regarding the new genera of coronaviridae that appear the first time in Wuhan, China, in early December 2019. Due to the continuous spreading of the novel COVID-19 with the exponential rise in death numbers, new therapeutic development is urgent, in general, there are no specific antiviral drugs or vaccines for 2019-novel coronavirus. Hence, this review may serve as an impetus for researchers working in the field of medical microbiology, vaccination, and antiviral drug design by discussion the most recent information about the antiviral action of AmB against COVID-19 infection as well as trying to a deep understanding of major properties, mechanisms of action, immune system responses, and antimicrobial efficiency of AmB. Since AmB is expected to alter the structure of the viral envelope, membrane integrity of cells, and internal cellular organelles, besides its other unique properties such as host immunomodulatory effects, so this review suggested that AmB as an effective anti-fungi drug thus may hold the promise of formulating a novel therapeutic option to treat COVID-19.
DOI : 10.4103/atm.ATM_147_20
Anahtar Kelimeler : amphotericin b, antimicrobial agents, antiviral drugs, coronavirus, covid-19
Cilt: 15
Sayı: 3
Sayfa: 118 - 124
Sınıflandırma :
17
COVID-19 and cancer care in Bermuda
Dergi Makalesi

Dergi Makalesi
Kaynak :
Science Direct
Dergi:
The Lancet Oncology
Yayıncı:
Elsevier
Yazar(lar) :
Christopher Fosker
Yıl :
2020
COVID-19 and cancer care in Bermuda
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
DOI : 10.1016/s1470-2045(20)30272-2
ISSN: 1470-2045
Sayı: 6
Cilt: 21
Sayfa: 761-762
Sınıflandırma :
18
Combating devastating COVID-19 by drug repurposing
Dergi Makalesi

Dergi Makalesi
Kaynak :
Science Direct
Dergi:
International Journal of Antimicrobial Agents
Yayıncı:
Elsevier
Yazar(lar) :
Ashish Yashwantrao Pawar
Yıl :
2020
Combating devastating COVID-19 by drug repurposing The recent pandemic of COVID- 19 (coronavirus disease 2019), caused by a viral infection with SARS-CoV-2 (severe acute respiratory syndrome coronavirus As no drugs are available to treat this life-threatening disease and the mortality rate due to COVID- 19 is high, there is an utmost need to attempt to This article emphasises possible drug candidates in the treatment of COVID- 19. Most of these drugs were found to be effective in in vitro studies. COVID-19
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
Despite advances in drug discovery, viral infections remain a major challenge for scientists across the globe. The recent pandemic of COVID-19 (coronavirus disease 2019), caused by a viral infection with SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), has created a disastrous situation all over the world. As no drugs are available to treat this life-threatening disease and the mortality rate due to COVID-19 is high, there is an utmost need to attempt to treat the infection using drug repurposing. Some countries are against the use of these drugs because of adverse effects associated with drug repurposing and lack of statistically significant clinical data, but they have been found to be effective in some countries to treat COVID-19 patients (off-label/investigational). This article emphasises possible drug candidates in the treatment of COVID-19. Most of these drugs were found to be effective in in vitro studies. There is a need to re-assess in vitro data and to carry out randomised clinical trials. Further investigations of these drugs are recommended on a priority basis.
DOI : 10.1016/j.ijantimicag.2020.105984
Anahtar Kelimeler : COVID-19, SARS-CoV-2, Drug repurposing, Coronavirus, CoV coronavirus, coronavirus, MERS-CoV Middle East respiratory syndrome coronavirus, Middle East respiratory syndrome coronavirus, SARS-CoV severe acute respiratory syndrome coronavirus, severe acute respiratory syndrome coronavirus
ISSN: 0924-8579
Sayı: 2
Cilt: 56
Sayfa: 105984
Sınıflandırma :
19
Regulators split on antimalarials for COVID-19
Dergi Makalesi

Dergi Makalesi
Kaynak :
Science Direct
Dergi:
The Lancet
Yayıncı:
Elsevier
Yazar(lar) :
Susan Jaffe
Yıl :
2020
Regulators split on antimalarials for COVID-19
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
DOI : 10.1016/s0140-6736(20)30817-5
ISSN: 0140-6736
Sayı: 10231
Cilt: 395
Sayfa: 1179
Sınıflandırma :
20
A Conceptual Deep Learning Framework for COVID-19 Drug Discovery
Konferans Bildirileri

Konferans Bildirileri
Kaynak :
IEEE Xplore
Yazar(lar) :
Mohammad Behdad Jamshidi , Jakub Talla , Ali Lalbakhsh , Maryam S. Sharifi-Atashgah , Asal Sabet , Zdenek Peroutka
Konu :
Communication, Networking and Broadcast Technologies, Components, Circuits, Devices and Systems, Computing and Processing, Fields, Waves and Electromagnetics, General Topics for Engineers, Power, Energy and Industry Applications, Robotics and Control Systems, Signal Processing and Analysis
Yıl :
2021
A Conceptual Deep Learning Framework for COVID-19 Drug Discovery Accordingly, a framework has been proposed to show how COVID- 19 drug development can benefit from the potentials of AI and DL. COVID-19 COVID-19 drug discovery covid-19
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
The analytical and experimental methods used for the development of drugs have some disadvantages in the aspect of the needed time for preparation of the desired pharmaceudical products and the efficiency of them, which not only can the risk for failure increase, particularly when pathogens are impossible to be cultivated under laboratory conditions, but these approaches can also lead to achieving arrays of antigens that are not able to provide sufficient immunity to combat the targeted disease. On the other hand, artificial intelligence (AI) and its new branches, including deep learning (DL) and machine learning (ML) techniques can be deployed for drug development purposes in order to alleviate the difficulties associated with conventional methods. Moreover, intelligent methods will provide researchers with the opportunity to use some user-friendly and efficient services to conquer such problems. In this respect, a conceptual DL framework has been studied in order to demonstrate the capability and applicability of these methods. Accordingly, a framework has been proposed to show how COVID-19 drug development can benefit from the potentials of AI and DL.
DOI : 10.1109/uemcon53757.2021.9666715
Anahtar Kelimeler : Drugs, Deep learning, COVID-19, Pathogens, Biomedical equipment, Medical services, Learning (artificial intelligence), diseases, drugs, laboratory techniques, learning (artificial intelligence), pharmaceutical industry, deep learning framework, COVID-19 drug discovery, analytical methods, failure risk, laboratory conditions, targeted disease, artificial intelligence, drug development, intelligent methods, parenthetical products, machine learning, DL framework, Artificial intelligence, bioinformatics, covid-19, deep learning, drug discovery, RNA, machine learning
Sınıflandırma :
21
Antimicrobial stewardship and COVID-19
Dergi Makalesi

Dergi Makalesi
Kaynak :
Springer Nature
Dergi:
BDJ In Practice
Yayıncı:
Springer Science and Business Media LLC
Yazar(lar) :
David CroserDavid Croser
Yıl :
2020
Antimicrobial stewardship and COVID-19
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
DOI : 10.1038/s41404-020-0558-6
ISSN: 2057-3308
Sayı: 11
Cilt: 33
Sayfa: 26-27
Sınıflandırma :
22
Directly Acting Antivirals for COVID-19: Where Do We Stand?
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
Frontiers in Microbiology
Yazar(lar) :
Siew L. Teoh , Yi H. Lim , Nai M. Lai , Nai M. Lai , Nai M. Lai , Shaun W. H. Lee , Shaun W. H. Lee , Shaun W. H. Lee
Yıl :
2020
Directly Acting Antivirals for COVID-19: Where Do We Stand? - 19). This rapid review aims to describe the directly acting antivirals that have been examined for use in the management of COVID- 19. - 19 to identify for case reports, case series, observational studies, and randomized controlled studies describing the use of antivirals in COVID- 19. COVID-19
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet Alıntıla
The outbreak of a novel coronavirus (SARS-CoV-2) in Wuhan, China in December 2019 has now become a pandemic with no approved therapeutic agent. At the moment, the genomic structure, characteristics, and pathogenic mechanisms of SARS-CoV-2 have been reported. Based upon this information, several drugs including the directly acting antivirals have been proposed to treat people with coronavirus disease 2019 (COVID-19). This rapid review aims to describe the directly acting antivirals that have been examined for use in the management of COVID-19. Searches were conducted in three electronic databases, supplemented with a search on arXiv, bioRxiv, medRxiv, ChinaXiv, ClinicalTrials.gov, and Chinese Clinical Trial Registry for studies examining the use of antivirals in COVID-19 to identify for case reports, case series, observational studies, and randomized controlled studies describing the use of antivirals in COVID-19. Data were extracted independently and presented narratively. A total of 98 studies were included, comprising of 38 published studies and 60 registered clinical trials. These drugs include the broad spectrum antivirals such as umifenovir, protease inhibitors such as lopinavir/ritonavir as well as the RNA-dependent RNA polymerase inhibitors, remdesivir, and favipiravir. Other drugs that have been used include the nucleosidase inhibitors and polymerase acidic endonuclease inhibitors which are currently approved for prevention of influenza infections. While some of the drugs appear promising in small case series and reports, more clinical trials currently in progress are required to provide higher quality evidence.
DOI : 10.3389/fmicb.2020.01857
Anahtar Kelimeler : rapid review, systematic review, COVID-19, antivirals, pandemic
ISSN: 1664-302X
Cilt: 11
Sınıflandırma :
23
Repositioning Chromones for Early Anti-inflammatory Treatment of COVID-19
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
Frontiers in Pharmacology
Yazar(lar) :
Piero Sestili , Vilberto Stocchi
Yıl :
2020
Repositioning Chromones for Early Anti-inflammatory Treatment of COVID-19 The COVID- 19 pandemic is posing an unprecedented sanitary threat. The repositioning of available drugs to treat COVID- 19 is the only and rapid option in the face of the lack of direct antiviral agents and vaccines available - 19’s worst complications. COVID-19
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet Alıntıla
The COVID-19 pandemic is posing an unprecedented sanitary threat. In the absence of specific vaccines and anti-SARS-CoV-2 drugs, medicines that may assist in tackling the emergency and limiting the high number of fatalities are urgently needed. The repositioning of available drugs to treat COVID-19 is the only and rapid option in the face of the lack of direct antiviral agents and vaccines available. In this light it is important to focus on available drugs, which, based on their pharmacodynamics, could plausibly attenuate viral growth as well as COVID-19’s worst complications. This is the case of chloroquine and tocilizumab which seem to limit virus replication and the severity of interstitial pneumonia, respectively. However, these treatments, particularly those aimed at containing inflammation, are still reserved for the most severe cases. This commentary elaborates on the pharmacological rationale of repositioning the mast cell stabilizer chromones as an adjunctive treatment for SARS‐CoV‐2 infection, and proposes their practical clinical testing as an early, safe, and cost-effective anti-inflammatory intervention in COVID-19 to limit the eventual secondary progression toward life-threatening respiratory complications.
DOI : 10.3389/fphar.2020.00854
Anahtar Kelimeler : COVID-19, inflammation, lung injury, chromones, mast cells
ISSN: 1663-9812
Cilt: 11
Sınıflandırma :
24
Artificial Intelligence for COVID-19 Drug Discovery and Vaccine Development
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
Frontiers in Artificial Intelligence
Yazar(lar) :
Arash Keshavarzi Arshadi , Julia Webb , Milad Salem , Emmanuel Cruz , Stacie Calad-Thomson , Niloofar Ghadirian , Jennifer Collins , Elena Diez-Cecilia , Brendan Kelly , Hani Goodarzi , Jiann Shiun Yuan
Yıl :
2020
Artificial Intelligence for COVID-19 Drug Discovery and Vaccine Development Understanding the pathobiology of COVID- 19 could aid scientists in their discovery of potent antivirals by elucidating unexplored viral pathways. In this review, we focus on the recent advances of COVID- 19 drug and vaccine development using artificial intelligence and the potential of intelligent training for the discovery of COVID- 19 therapeutics. COVID-19
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet Alıntıla
SARS-COV-2 has roused the scientific community with a call to action to combat the growing pandemic. At the time of this writing, there are as yet no novel antiviral agents or approved vaccines available for deployment as a frontline defense. Understanding the pathobiology of COVID-19 could aid scientists in their discovery of potent antivirals by elucidating unexplored viral pathways. One method for accomplishing this is the leveraging of computational methods to discover new candidate drugs and vaccines in silico. In the last decade, machine learning-based models, trained on specific biomolecules, have offered inexpensive and rapid implementation methods for the discovery of effective viral therapies. Given a target biomolecule, these models are capable of predicting inhibitor candidates in a structural-based manner. If enough data are presented to a model, it can aid the search for a drug or vaccine candidate by identifying patterns within the data. In this review, we focus on the recent advances of COVID-19 drug and vaccine development using artificial intelligence and the potential of intelligent training for the discovery of COVID-19 therapeutics. To facilitate applications of deep learning for SARS-COV-2, we highlight multiple molecular targets of COVID-19, inhibition of which may increase patient survival. Moreover, we present CoronaDB-AI, a dataset of compounds, peptides, and epitopes discovered either in silico or in vitro that can be potentially used for training models in order to extract COVID-19 treatment. The information and datasets provided in this review can be used to train deep learning-based models and accelerate the discovery of effective viral therapies.
DOI : 10.3389/frai.2020.00065
Anahtar Kelimeler : COVID-19, SARS-COV-2, vaccine, artificial intelligence, deep learning
ISSN: 2624-8212
Cilt: 3
Sınıflandırma :
25
Progress in the Research and Development of Anti-COVID-19 Drugs
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
Frontiers in Public Health
Yazar(lar) :
Lianzhou Huang , Yuanqiu Chen , Ji Xiao , Weisheng Luo , Feng Li , Yuan Wang , Yiliang Wang , Yifei Wang
Yıl :
2020
Progress in the Research and Development of Anti-COVID-19 Drugs COVID- 19 spread rapidly around the world in a short time. of specific drugs for the treatment of COVID- 19. We also discussed the strategies of the development of anti- COVID- 19 drugs in the future. COVID-19 anti-COVID-19 drugs
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet Alıntıla
The outbreaks of COVID-19 due to SARS-CoV-2 has caused serious physical and psychological damage to global human health. COVID-19 spread rapidly around the world in a short time. Confronted with such a highly infectious respiratory disease, the research and development of anti-COVID-19 drugs became an urgent work due to the lack of specific drugs for the treatment of COVID-19. Nevertheless, several existing drugs are available to relieve the clinical symptoms of COVID-19. We reviewed information on selected anti-SARS-CoV-2 candidate therapeutic agents published until June 2, 2020. We also discussed the strategies of the development of anti-COVID-19 drugs in the future. Our review provides a novel insight into the future development of a safer, efficient, and toxic-less anti-COVID-19 drug.
DOI : 10.3389/fpubh.2020.00365
Anahtar Kelimeler : COVID-19, SARS-CoV-2, anti-COVID-19 drugs, remdesivir, lopinavir/ritonavir, chloroquine
ISSN: 2296-2565
Cilt: 8
Sınıflandırma :
26
COVID-19 and early human milk lactoferrin
Dergi Makalesi

Dergi Makalesi
Kaynak :
Taylor and Francis
Dergi:
The Journal of Maternal-Fetal & Neonatal Medicine
Yayıncı:
Informa UK Limited
Yazar(lar) :
Beuy Joob , Viroj Wiwanitkit
Yıl :
2021
COVID-19 and early human milk lactoferrin
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
DOI : 10.1080/14767058.2021.1960971
ISSN: 1476-7058
Sayfa: 1-1
Sınıflandırma :
27
Tamoxifen from chemotherapy to antiviral drug: Possible activity against COVID-19
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
Biomedical and Biotechnology Research Journal
Yazar(lar) :
Huda Ali Salman Almosawey , Falah Hasan Obayes AL-Khikani , Raghdah Maytham Hameed , Younus Jasim Abdullah , Mohanad Kadhim Mirdan Al-Ibraheemi , Atyaf Ali Al-Asadi
Yıl :
2020
Tamoxifen from chemotherapy to antiviral drug: Possible activity against COVID-19 Coronavirus disease 2019 ( COVID- 19) is regarding the new genera of coronaviredia that appeared for the first time in Wuhan, China, in early December 2019 Due to the continuous spread of the novel COVID- 19 with the exponential rise in death numbers, new therapeutic development is urgent; in general, there Hence, this review will discuss the most recent information about the antiviral action of TAM against COVID- 19 infection by trying to give a deep understanding covid-19
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet Alıntıla
Tamoxifen (TAM) is the oldest and the most-prescribed selective estrogen receptor modulator (SERM). It is a member of the triphenylethylene group. TAM has been used to treat breast cancer that spreads to other parts of the human body; it is also utilized to decreasing the chances of breast cancer developing in high-risk patients. Recently, some studies focused on the potential antimicrobial action of TAM. Coronaviruses are enveloped positive-sense RNA nucleic acid viruses that have club-like spikes, characterized by a distinctive replication strategy; they are round and sometimes pleomorphic in shape. Coronavirus disease 2019 (COVID-19) is regarding the new genera of coronaviredia that appeared for the first time in Wuhan, China, in early December 2019. Due to the continuous spread of the novel COVID-19 with the exponential rise in death numbers, new therapeutic development is urgent; in general, there are no specific antiviral drugs or vaccines for 2019-nCoV. Hence, this review will discuss the most recent information about the antiviral action of TAM against COVID-19 infection by trying to give a deep understanding of major properties, mechanisms of action, immune system responses, and antimicrobial efficiency of TAM that is regarding the promising way to treat COVID-19 novel infection. The current review may serve as an impetus for researchers working in the field of medical microbiology, vaccination, and antiviral drug design. The review also rationally reports and critically analyzes the available knowledge by focusing and mentioning future steps and strategies trying to find appropriate solutions regarding challenges in COVID-19 management by TAM utilization.
DOI : 10.4103/bbrj.bbrj_53_20
Anahtar Kelimeler : antimicrobial agents, antiviral drugs, chemotherapy, coronavirus, covid-19, tamoxifen
Cilt: 4
Sayı: 2
Sayfa: 108 - 116
Sınıflandırma :
28
Signal amplification by reversible exchange for COVID-19 antiviral drug candidates
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
Scientific Reports
Yazar(lar) :
Hye Jin Jeong , Sein Min , Heelim Chae , Sarah Kim , Gunwoo Lee , Sung Keon Namgoong , Keunhong Jeong
Yıl :
2020
Signal amplification by reversible exchange for COVID-19 antiviral drug candidates Abstract Several drug candidates have been proposed and tested as the latest clinical treatment for coronavirus pneumonia ( COVID- 19). This technique may provide new opportunities in diagnosis and research of COVID- 19.
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet Alıntıla
Abstract Several drug candidates have been proposed and tested as the latest clinical treatment for coronavirus pneumonia (COVID-19). Chloroquine, hydroxychloroquine, ritonavir/lopinavir, and favipiravir are under trials for the treatment of this disease. The hyperpolarization technique has the ability to further provide a better understanding of the roles of these drugs at the molecular scale and in different applications in the field of nuclear magnetic resonance/magnetic resonance imaging. This technique may provide new opportunities in diagnosis and research of COVID-19. Signal amplification by reversible exchange-based hyperpolarization studies on large-sized drug candidates were carried out. We observed hyperpolarized proton signals from whole structures, due to the unprecedented long-distance polarization transfer by para-hydrogen. We also found that the optimal magnetic field for the maximum polarization transfer yield was dependent on the molecular structure. We can expect further research on the hyperpolarization of other important large molecules, isotope labeling, as well as polarization transfer on nuclei with a long spin relaxation time. A clinical perspective of these features on drug molecules can broaden the application of hyperpolarization techniques for therapeutic studies.
DOI : 10.1038/s41598-020-71282-6
ISSN: 2045-2322
Cilt: 10
Sayı: 1
Sayfa: 1 - 13
Sınıflandırma :
29
COVID-19 update: The race to therapeutic development
Dergi Makalesi

Dergi Makalesi
Kaynak :
Science Direct
Dergi:
Drug Resistance Updates
Yayıncı:
Elsevier
Yazar(lar) :
Julianne D. Twomey , Shen Luo , Alexis Q. Dean , William P. Bozza , Ancy Nalli , Baolin Zhang
Yıl :
2020
COVID-19 update: The race to therapeutic development The COVID- 19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), represents an unprecedented challenge to global public health At the time of this review, COVID- 19 has been diagnosed in over 40 million cases and associated with 1.1 million deaths worldwide. We highlight two major lines of therapeutic strategies for COVID- 19 treatment: 1) repurposing the existing drugs for use in COVID- 19 patients, such as COVID-19
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), represents an unprecedented challenge to global public health. At the time of this review, COVID-19 has been diagnosed in over 40 million cases and associated with 1.1 million deaths worldwide. Current management strategies for COVID-19 are largely supportive, and while there are more than 2000 interventional clinical trials registered with the U.S. National Library of Medicine (clinicaltrials.gov), results that can clarify benefits and risks of candidate therapies are only gradually becoming available. We herein describe recent advances in understanding SARS-CoV-2 pathobiology and potential therapeutic targets that are involved in viral entry into host cells, viral spread in the body, and the subsequent COVID-19 progression. We highlight two major lines of therapeutic strategies for COVID-19 treatment: 1) repurposing the existing drugs for use in COVID-19 patients, such as antiviral medications (e.g., remdesivir) and immunomodulators (e.g., dexamethasone) which were previously approved for other disease conditions, and 2) novel biological products that are designed to target specific molecules that are involved in SARS-CoV-2 viral entry, including neutralizing antibodies against the spike protein of SARS-CoV-2, such as REGN-COV2 (an antibody cocktail), as well as recombinant human soluble ACE2 protein to counteract SARS-CoV-2 binding to the transmembrane ACE2 receptor in target cells. Finally, we discuss potential drug resistance mechanisms and provide thoughts regarding clinical trial design to address the diversity in COVID-19 clinical manifestation. Of note, preventive vaccines, cell and gene therapies are not within the scope of the current review.
DOI : 10.1016/j.drup.2020.100733
Anahtar Kelimeler : COVID-19, SARS-CoV-2, Virus life cycle, Therapeutic targets, Drug development, Antivirals, Immunomodulators, Monoclonal antibodies, ACE2, Spike protein, Repurposed use, Existing drugs
ISSN: 1368-7646
Sayfa: 100733
Sınıflandırma :

Yayın Yılı

Sınırla

Doküman Türü
Tümü

Veri Tabanı
Tümü

Dergi İsmi
Tümü

Disiplin
Tümü

Disipline Göre İlgililik

Alt Disiplin
Tümü

Konu
Tümü

Yayıncı
Tümü

Lisan
Tümü

X
Filtreler